Neurovascular damage in experimental allergic encephalomyelitis: A target for pharmacological control

Mediators of Inflammation

Volumn 6, Issue 5-6, 1997, Pages 295-302

  Bolton, C ^a  

^a University of Bath   (United Kingdom)

Author keywords

Blood brain barrier; Cyclosporin; Glucocorticoids; MK 801; N methyl D aspartate receptor; Polyamines

Indexed keywords

ALBUMIN; CYCLOSPORIN A; DEXAMETHASONE; DIZOCILPINE; GLUCOCORTICOID; HORSERADISH PEROXIDASE; MANNITOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PRAZOSIN; TUFTSIN;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

EID: 0031467484     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359791415     Document Type: Review

References (103)

1. Bar T. The vascular system of the cerebral cortex. Adv Anat Embryo Cell Biol 1980; 59: 1-62.
2. Shepro D, Morel NML. Pericyte physiology FASEB J 1993; 7: 1031-1038.
3. Crone C. The blood-brain barrier: a modified tight epithelium. In: Suckling AJ, Rumsby MG, Bradbury MWB, eds. The Blood-Brain Barrier in Health and Disease. Chichester: Ellis Horwood, 1986; 17-40.
4. Goldstein GW, Betz AL. The blood-brain barrier. Sci Am 1986; 255: 70-79.
5. Goldstein GW. Endothelial cell astrocyte interactions. A cellular model of the blood-brain barrier. Ann NY Acad Sci 1988; 529: 31-39.
6. Engelbardt B, Risau W. Development of the blood-brain barrier. In: Greenwood J, Begley DJ, Segal MB, eds. New Concepts of a Blood Brain Barrier New York: Plenum Press, 1995; 11-31.
7. Cervos-Navarro J, Kannuki S, Nakagawa Y. Blood-brain barrier (BBB). Review from morphological aspect. Histol Histopath 1988; 3: 203-213.
8. Betz AL, Firth JA, Goldstein GW. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of the brain capillary endothelial cells. Brain Res 1980; 192: 17-28.
9. Kreutzberg GW, Tóth L. Enzyme cytochemistry of the cerebral microvessel wall. Acta Neuropathol 1983; 8: 35-41.
10. Joó F. The blood-brain barrier in vitro: ten years of research on microvessels isolated from the brain. Neurochem Int 1985; 7: 1-25.
11. Fernstermacher JD, Wei L, Acuff V, et al. The dependency of influx across the blood-brain barrier on blood flow and the apparent flow-independence of glucose influx during stress. In: Greenwood J. Begley DJ, Segal MB, eds. New Concepts of a Blood-Brain Barrier. New York: Plenum Press, 1995; 89-101.
12. Abbott NJ, Courand PO, Roux F, Begley DJ. Studies on an immortalized brain endothelial cell line: characterisation, permeability and transport. In: Greenwood J, Begley DJ, Segal MB, eds. New Concepts of a Blood Brain Barrier. New York: Plenum Press, 1995; 239-249.
13. Bodor N, Brewster M. Problems of delivery of drugs to the brain. Pharmacol Ther 1983; 19: 337-386.
14. Betz AL, Goldstein GW. Specialised properties and solute transport in brain capilliaries. Ann Rev Physio 1986; 48: 142-250.
15. Banks WA, Kastin AJ. Interactions between the blood-brain barrier and endogenous peptides: emerging clinical implications. Am J Med Sci 1988; 295: 459-465.
16. Moor ACE, De Vries HE, De Boer AG, Breimer DD. The blood-brain barrier and multiple sclerosis. Biochem Pharmacol 1994; 47: 1717-1724.
17. Lam DKC. The blood-central nervous system barrier in acute experimental allergic encephalomyelitis. In: Suckling AJ, Rumsby MG, Bradbury MWB. eds. The Blood-Brain Barrier in Health and Disease. Chichester: Ellis Horwood, 1986; 17-40.
18. Medawar PB. Immunity to homologous grafted skin III. The fate of skin homogratts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29: 58-69.
19. Wilcox CE, Baker D, Butter C, Willoughby DA, Turk JL. Differential expression of guinea pig class II major histocompatibility complex antigens on vascular endothelial cells in vitro and in experimental allergic encephalomyelitis. Cell Immunol 1989; 120: 82-91.
20. Fabry Z, Waldschmidt MM, Hendrickson DK, et al. Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp55. J Neuroimmunol 1992; 36: 1-11.
21. Paterson PY. Experimental autoimmune (allergic) encephalomyelitis: induction, pathogenesis and suppression. In: Meischer PA, Mueller-Eberhard HJ, eds. Textbook of Immunopathology. New York: Grune & Stratton, 1976; 179-213.
22. Linthicum DS, Munoz JJ, Blaskett A. Acute experimental autoimmune encephalomyelitis in mice. 1. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitisation and increased vascular permeability of the central nervous system. Cell Immunol 1982; 73: 299-310.
23. Dux E, Joo F. Effects of histamine on brain capillaries: fine structural and immunohistochemical studies after intracarotid infusion. Exp Brain Res 1982; 47: 252-258.
24. Orr EL, Stanley NC. Brain and spinal cord levels of histamine in Lewis rats with acute experimental autoimmune encephalomyelitis. J Neurochem 1989; 53: 111-118.
25. Waxman FJ, Taguiam JM, Whitacre CC. Modification of clinical and histopathologic expression of experimental allergic encephalomyelitis by a vasoactive amine antagonist - cyproheptidine. Cell Immunol 1984; 85: 82-93.
26. Bolton C, Gordon D, Turk JL. A longitudinal study of the prostaglandin content of central nervous system tissues from guinea pigs with acute experimental encephalomyelitis. Int J Immunopharmac 1984; 6: 155-161.
27. Bolton C, Parker D, McLeod J, Turk JL. A study of the prostaglandin and thromboxane content of the central nervous tissues with the development of chronic relapsing allergic encephalomyelitis. J Neuroimmunol 1986; 10: 201-208.
28. Bolton C, Turner AM, Turk JL, Prostaglandin levels in cerebrospinal fluid from multiple sclerosis patients in remission and relapse. J Neuroimmunol 1984; 6: 151-159.
29. Bolton C, Cuzner ML. Modification of EAE by non-steroidal anti-inflammatory drugs. In: Davison AN, Cuzner ML, eds. The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis. London: Academic Press, 1980; 189-198.
30. Mannie MD, Pope L, Paterson PY. Indomethacin augments in vitro proliferative responses of Lewis rat lymphocytes to myelin basic protein - implications for experimental allergic encephalomyelitis. Cell Immunol 1989; 121: 196-212.
31. Henning B, Goldblum S, McClain C. Interleukin-1 and tumor necrosis factor/cachectin increase endothelial permeability in vitro. J Leukoc Biol 1987; 42: 551.
32. Brett J, Gerlach H, Nawroth P, Steinberg S, Godman G, Stern D. Tumour necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med 1989; 169: 1977-1991.
33. Kuroda Y, Shimamoto Y. Human tumor necrosis factor-α augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 1991; 34: 159-164.
34. Baker D, O'Neill JK, Turk JL. Cytokines in the central nervous system of mice during chronic relapsing allergic encephalomyelitis. Cell Immunol 1991; 134: 505-510.
35. Sharief MK, Thompson EJ. In vivo relationship of tumour necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 1992; 38: 27-34.
36. Scott GS, Paul C, Whitehouse J, Williams KI, Bolton C. Immunomodulation of nitric oxide (NO) and its contribution to neurovascular permeability during experimental allergic encephalomyelitis (EAE). Inflamm Res 1995; 44: S223.
37. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994; 93: 2684-2690.
38. Ruuls SR, Van der Linden S, Huitinga I, Dijkstra CD. Nitric oxide as immunesuppressor in experimental allergic encephalomyelitis. J Neuroimmunol 1994; 54: 193.
39. Zielasek JJ, Jung S, Gold R, Liew FY, Toyka KV, Hartung H-P. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autommune encephalomyelitis. J Neuroimmunol 1995; 58: 81-88.
40. Scott GS, Williams KI, Bolton C. A pharmacological study on the role of nitric oxide in the pathogenesis of experimental allergic encephalomyelitis. Inflamm Res 1996; 45: 524-529.
41. Paul C, Scott GS, Harbour M, Seiler N, Bolton C. N-methyl-D-aspartate (NMDA) receptor-mediated events contribute to neurovascular breakdown during experimental allergic encephalomyelitis (EAE). Biochem Soc Trans 1997; 25: 1665.
42. Koenig H, Goldstone AD, Lu CY. Blood-brain barrier breakdown in brain edema following cold injury is mediated by microvascular polyamines. Biochem Biophys Res Commun 1983; 116: 1039-1048.
43. Koenig H, Goldstone AD, Lu CY. Blood brain barrier breakdown in cold-infused brain is linked to a biphasic stimulation of ornithine decarboxylase activity and polyamine synthesis: both are coordinately inhibited by verapamil, dexamethasone, and aspirin. J Neurochem 1989; 52: 101-109.
44. Garthwaite J, Garthwaite G, Palmer RMJ, Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989; 172: 413-416.
45. Koenig H, Goldstone AD, Lu CY, Troat JJ. Brain polyamines are controlled by N-methyl-D-aspartate receptors during ischemia and recirculation. Stroke 1990; 21: 98-111.
46. Koenig H, Trout JJ, Goldstone AD, Lu CY. Capillary NMDA receptors regulate blood-brain barrier function and breakdown. Brain Res 1992; 588: 297-303.
47. Bolton C, Paul C. MK-801 limits neurovascular dysfunction in experimental allergic encephalomyelitis. J Pharm Exp Therap 1997; 282: 397-402.
48. Paul C, Seiler NB, Bolton C. Pharmacological evidence of a role for N-methyl-D-aspartate (NMDA) receptor generated polyamines in neurovascular breakdown during experimental allergic encephalomyelitis (EAE). J Neuroimmunol (in press).
49. Wallstrom H, Diener P, Ljungdahl A, Khademi M, Nilsson C-G, Olsson T. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol sci 1996; 137: 89-96.
50. Claudio L, Kressy Y, Norton WT, Brosnan CF. Increased vesicular transport and decreased mitochondrial content in blood-brain barrier endothelial cells during experimental allergic encephalomyelitis. Am J Pathol 1989; 135: 1157-1168.
51. Hawkins CP, Munro PMG, London DN, McDonald WI. Metabolically dependent blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis. Acta Neuropathol 1992; 83: 630-635.
52. Oldendorf WH, Cornford ME, Brown WJ. The large apparent work capacity of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol 1977; 1: 409-417.
53. Kato S, Nakamura H. Ultrastructural and ultracytochemical studies on the blood-brain barrier in chronic relapsing experimental allergic encephalomyelitis. Acta Neuropathol 1989; 77: 455-464.
54. Pender MP. Demyelination and neurological signs in experimental allergic encephalomyelitis. J Neurol 1987; 15: 11-24.
55. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79: 319-326.
56. Hartung H-P, Jung S, Stoll G, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992; 40: 197-210.
57. Barlow CF. A study of abnormal blood-brain barrier permeability in experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 1956; 15: 196-208.
58. Vulpe NM, Hawkins A, Rozdilsky B. Permeability of cerebral blood vessels in experimental allergic encephalomyelitis studied by radioactive iodinated bovine albumin. Neurology 1960; 10: 171-177.
59. 125I gamma globulin and leucocytes in allergic encephalomyelitis. J Neuropath Exp Neurol 1967; 26: 558-571.
60. Oldstone MBA, Dixon FJ. Immunohistochemical study of allergic encephalomyelitis. Am J Path 1968; 52: 251-263.
61. Leibowitz S, Kennedy L. Cerebral vessel permeability and cellular infiltration in experimental allergic encephalomyelitis. Immunology 1972; 22: 859-869.
62. Lampert P, Carpenter S. Electron microscopic studies of the vascular permeability and the mechanism of demyelination in experimental allergic encephalomyelitis. J Neuropath Exp Neurol 1965; 24: 11-24.
63. Hirano A, Dembitzer HM, Becker NH, Levine S, Zimmerman HM. Fine structural alterations of the blood-brain barrier in experimental allergic encephalomyelitis. J Neuropath Exp Neurol 1970; 29: 432-440.
64. Hawkins CP, Munro PMG, Mackenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium DTPA and protein markers. Brain 1990; 113: 365-378.
65. Stewart WA, Alvord EC, Hruby S, Hall LD, Paty DW. Early detection of experimental allergic encephalomyelitis by magnetic resonance imaging. Lancet 1985; ii: 898.
66. Kuharik MA, Edwards MK, Farlow MR, et al. Gd-enhanced MR imaging of acute and chronic experimental demyelinating lesions. Am J Neuroradiol 1988; 9: 643-648.
67. Grossman RI, Lisak RP, Macchi PJ, Joseph PM. MR of acute experimental allergic encephalomyelitis. Am J Neuroradiol 1987; 8: 1045-1048.
68. Brown WJ. The capillaries in acute and subacute multiple sclerosis - a morphometric analysis. Neurology 1978; 28: 84-92.
69. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-939.
70. Hawkins CP, Mackenzie F, Tofts P, Du Boulay EPGH, McDonald WI. Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 1991; 114: 801-810.
71. Morrisey SP, Stodal H, Zettl U, et al. In vivo MRI and its histological correlaters in acute adoptive transfer experimental allergic encephalomyelitis. Brain 1996; 119: 239-248.
72. Namer IJ, Steibel J, Poulet P, et al. Blood-brain barrier breakdown in MBP-specific T cell induced experimental allergic encephalomyelitis. Brain 1993; 116: 147-149.
73. Reese TS, Karnovsky MSJ. Fine structural localisation of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967; 34: 207-217.
74. Brightman MW, Reese TS. Junctions between intimately opposed cell membranes in the vertebrate brain. J Cell Biol 1969; 40: 648-677.
75. Claudio L, Kress Y, Norton WT, Brosnan CF. Increased vesicular transport and decreased mitochondrial content in blood-brain barrier endothelial cells during experimental autoimmune encephalomyelitis. Am J Pathol 1989; 135: 1157-1168.
76. Lossinsky AS, Badmajew V, Robson JA, Moretz RC, Wisniewski HM. Sites of egress of inflammatory cells and horseradish peroxidase transport across the blood-brain barrier in a murine model of chronic relapsing experimental allergic encephalomyelitis. Acta Neuropathol 1989; 78: 359-371.
77. Vorbrodt AW. The application of quantitative immunocytochemistry for the evaluation of blood-brain barrier (BBB) to endogenous albumin. In: Greenwood J, Begley DJ, Segal MB, eds. New Concepts of a Blood-Brain Barrier. New York: Plenum Press, 1995; 39-16.
78. Zlokovic BV, Lipovac MN, Begley DJ, Dawson H, Rakic L. Slow penetration of thyrotropin releasing hormone across the blood-brain barrier of in situ perfused guinea-pig brain. J Neurochem 1988; 51: 252-257.
79. Oldendorf WH, Towner HF. Blood-brain barrier and DNA changes during the evolution of experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 1974; 33: 616-631.
80. Daniel PM, Lam DKC, Pratt OB. Changes in the effectiveness of the blood-brain barrier and blood-spinal cord barrier in experimental allergic encephalomyelitis. J Neurol Sci 1981; 52: 211-219.
81. Paul C, Bolton C. Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone and cyclosporin A. Int J Immunopharm 1995; 17: 497-503.
82. 99mTc RP128 in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis. J Nuclear Med 1997; 38: 187P.
83. Wahl M, Schilling L, Unterberg A, Baethmann A. Autocoids as mediators of vasogenic brain oedema. In: Greenwood J, Begley DJ, Segal MB, eds. New Concepts of a Blood-Brain Barrier. New York: Plenum Press, 1995; 147-148.
84. Long JB, Holladay JW. Blood-brain barrier: endogenous modulation by adrenal-cortical function. Science 1985; 227: 1580-1583.
85. Hedley-Whyte ET, Hsu DW. Effect of dexamethasone on the blood-brain barrier in the normal mouse. Ann Neurol 1986; 19: 373-377.
86. Zlylan YZ, Le Fauconnier UJM, Bernard G, Bourre JM. Effects of dexamethasone on transport of α-aminobutyric acid across the blood-brain barrier. J Neurochem 1988; 51: 1338-1342.
87. Levine S, Sowinski R. Therapy of allergic encephalomyelitis in rats after onset of paralysis. In: Davison AN, Cuzner ML, eds. The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis. London: Academic Press, 1980; 199-209.
88. MacPhee IAM, Antoni FA, Mason DW. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 1989; 169: 431-445.
89. Bolton C, Flower RJ. The effects of the anti-glucocorticoid RU38486 on steroid-mediated supression of experimental allergic encephalomyelitis in the Lewis rat. Life Sci 1989; 45: 97-104.
90. De Kloet ER, Cousin MA, Veldhuis HD, Voorhuis TD, Lando D. Glucocorticoids modulate the response of ornithine decarboxylase to unilateral removal of the dorsal hippocampus. Brain Res 1983; 275: 91-98.
91. Jung-Testas I, Renoir M, Bugnard H, Greene GL, Baulieu E. Demonstration of steroid hormone receptors and steroid action in primary cultures of rat glial cells. J Steroid Biochem Mol Biol 1992; 41: 621-631.
92. Brosnan CF, Goldmuntz EA, Cammer W, Factor SM, Bloom BR, Norton WT. Prazosin an alpha-1 adrenergic receptor antagonist, suppresses experimental autoimmune encephalomyelitis in the Lewis rat. Proc Natl Acad Sci USA 1985; 82: 5915-5921.
93. Goldmuntz EA, Brosnan CF, Norton WT. Prazosin treatment suppresses increased vascular permeability in both acute and passively transferred experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1986; 137: 3444-3450.
94. Rumjanek VM, Smith LA, Morley J. Modulation by cyclosporin-A of mononuclear cell distribution during experimental allergic encephalomyelitis. Int J Immunopharmacol 1984; 6: 99-104.
95. Reiber H, Suckling AJ. Cyclosporin-A treatment of experimental allergic encephalomyelitis: changes in immunological regulation and blood-CSF barrier function. J Neuroimmunol 1986; 12: 121-130.
96. Rego A, Vargas R, Cathapermal S, Kuwahara M, Foegh ML, Ramwell PW. Systemic vascular effects of cyclosporin A treatment in normotensive rats. J Pharmacol Exp Ther 1991; 259: 905-915.
97. Gallego MJ, Farre AL, Riesco A, et al. Blockade of endothelium-dependent responses in conscious rats by cyclosporin A: effect of L-arginine. Am J Physiol Heart Circ Physiol 1993; 264: H708-H714.
98. Ryffel B. Cyclosporin binding proteins. Identification, distribution, function and relation to FK binding proteins. Biochem Pharmacol 1993; 46: 1-12.
99. Begley DJ, Squires LK, Zlokovic BV, et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem 1990; 55: 1222-1230.
100. Wang Q, Yang H, Miller DW, Elmquist WF. Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Comm 1995; 211: 719-726.
101. Sakata A, Tama I, Kawazuk K, et al. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem Pharmacol 1994; 48: 1989-1992.
102. Begley DJ, Evans JE. Vincristine in therapeutic doses appears to increase blood-brain permeability to colchicine in the anaesthetised guinea-pig. J Physiol 1992; 446: 449P.
103. Drion M, Lemarie M, Lefauconnier JM, Scherrmann JM. Role of p-glycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurol 1996; 67: 1668-1693.